(S)-Ibuprofen is a low volume but high value pharmaceutical product which is categorized as nonsteroidal anti-inflammatory drug (NSAID). This precious chiral drug may be produced using racemic ibuprofen as raw material through the dynamic kinetic resolution. In this work, a simulation of (5)ibuprofen production is carried out using ASPEN PLUS (R) process simulation software. A pilot scale production with the capacity of 500 g/day of (S)-ibuprofen acid is considered in the present study. The product is synthesized through a three-step process: (i) substrate preparation via esterification; (ii) enzymatic dynamic kinetic resolution of substrate ester and (iii) product purification. Mass and energy balances of major equipment were calculated. The performance of the enzyme-mediated membrane reactor (EMR) was investigated by manipulating substrate and base concentrations as well as the flow rates. Besides, a number of issues related to the evaporation and crystallization of the product were identified and addressed. It was found that the optimum operating condition of EMR at 40 degrees C, 50-100 ml/min lumen flow rate with substrate and base concentrations, respectively at 10-20 mM and 60-100 mM, gave 0.92 conversion and 0.9 ee(p) of the product. An overall yield of 82.5% product crystal was achieved by operating the cooling-crystallizer in the temperature range of 5-10 degrees C. (C) 2010 Elsevier B.V. All rights reserved.